10 results on '"Falvo, Francesca"'
Search Results
2. Werner syndrome: a rare mutation
- Author
-
Castagna, Alberto, Gareri, Pietro, Falvo, Francesca, Sestito, Simona, Rocca, Maurizio, Pensabene, Licia, Concolino, Daniela, Coppolino, Giuseppe, and Ruotolo, Giovanni
- Published
- 2019
- Full Text
- View/download PDF
3. Norrbottnian clinical variant of Gaucher disease in Southern Italy
- Author
-
Sestito, Simona, Filocamo, Mirella, Ceravolo, Ferdinando, Falvo, Francesca, Grisolia, Michele, Moricca, Maria Teresa, Cantaffa, Renato, Grossi, Serena, Strisciuglio, Pietro, and Concolino, Daniela
- Published
- 2017
- Full Text
- View/download PDF
4. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
- Author
-
Ceravolo, Ferdinando, Grisolia, Michele, Sestito, Simona, Falvo, Francesca, Moricca, Maria Teresa, and Concolino, Daniela
- Subjects
GAUCHER'S disease treatment ,THERAPEUTIC use of enzymes ,GLUCOSYLCERAMIDES ,RECOMBINANT proteins ,GLYCOSPHINGOLIPIDS ,COMBINATION drug therapy ,THERAPEUTICS ,BLOOD-brain barrier ,DRUG therapy ,CHRONIC diseases ,COMBINED modality therapy ,ENZYME inhibitors ,GLYCOSIDASES ,INTRAVENOUS therapy ,PIPERIDINE - Abstract
Background: The variants of neuronopathic Gaucher disease may be viewed as a clinical phenotypic continuum divided into acute and chronic forms. The chronic neuronopathic form of Gaucher disease is characterized by a later onset of neurological symptoms and protracted neurological and visceral involvement. The first-choice treatment for nonneuronopathic Gaucher disease is enzyme replacement therapy with recombinant analogues of the deficient human enzyme glucocerebrosidase. Enzyme replacement therapy has been shown to improve hematological and bone manifestations associated with Gaucher disease, but, as with most proteins, recombinant enzymes cannot cross the blood-brain barrier, which prevents effects on neurological manifestations. Substrate reduction therapy with miglustat (N-butyldeoxynojirimycin) inhibits glucosylceramide synthase, which catalyzes the first step in glycosphingolipid synthesis. Because miglustat can cross the blood-brain barrier, it has been suggested that, combined with enzyme replacement therapy, it might be effective in treating neurological symptoms in patients with neuronopathic Gaucher disease.Case Presentation: We report observed effects of combined enzyme replacement therapy and substrate reduction therapy in a 7-year-old Caucasian boy with neuronopathic Gaucher disease who was homozygous for L444P mutations. He had received enzyme replacement therapy from the age of 18 months, and concomitant miglustat treatment was commenced, with dosing according to body surface area uptitrated over 1 month with dietary modifications when he reached the age of 30 months. He experienced mild diarrhea after commencing miglustat therapy, which decreased in frequency/severity over time. His splenomegaly was reduced, and his hematological values and plasma angiotensin-converting enzyme activity normalized. Plasma chitotriosidase also showed substantial and sustained decreases. After 5 years of combination therapy, the patient showed no signs of neurological impairment.Conclusions: This case supports the concept that oral miglustat in combination with intravenous enzyme replacement therapy may be beneficial in preventing neurological signs in patients with chronic neuronopathic Gaucher disease. The importance of dietary modifications has also been confirmed. Further follow-up studies are needed to better define the therapeutic effect of combined treatment in this Gaucher disease subtype. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
5. Neuronopathic Gaucher Disease.
- Author
-
Sestito, Simona, Falvo, Francesca, Grisolia, Michele, Nicoletti, Angela, Pascale, Elisa, Moricca, Maria Teresa, Esposito, Sara, Salpietro, Vincenzo, Polizzi, Agata, Ruggieri, Martino, and Concolino, Daniela
- Subjects
- *
GAUCHER'S disease , *PHENOTYPES , *THERAPEUTIC use of enzymes , *LYSOSOMAL storage diseases , *GENETICS , *DISEASE risk factors - Abstract
Gaucher disease (GD) has been classically divided into three phenotypes primarily according to the absence (type 1 GD or nonneuronopathic GD) or presence and severity (types 2 and 3 GD or neuronopathic GD) of neurological involvement. Despite such distinction, neurological manifestations have been recorded also in patients with type 1 GD: in this latter form, however, such manifestations are different and, in the majority of cases, of much less severity than those associated with types 2 and 3 GD. Significant advances in therapy have been achieved, primarily after the advent of enzyme replacement therapy (ERT). As it occurs in patients with type 1 GD, ERT is able to reverse systemic and extraneurological manifestations of type 3 GD, although evidence suggests that ERT is not able to prevent the progression of neurological involvement in the long term. Thus, it is necessary to better understand the pathophysiological mechanism underlying neurological involvement in GD patients, allowing the development of new therapeutic approaches capable of improving central nervous system manifestations in GD. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. The Different Forms of Mucopolysaccharidosis with Neurological Involvement: A Case-Based Review.
- Author
-
Falvo, Francesca, Sestito, Simona, Nicoletti, Angela, Grisolia, Michele, Mascaro, Italia, Pascale, Elisa, Salpietro, Vincenzo, Polizzi, Agata, Ruggieri, Martino, and Concolino, Daniela
- Subjects
- *
MUCOPOLYSACCHARIDOSIS treatment , *CENTRAL nervous system , *LYSOSOMAL storage diseases , *GLYCOSAMINOGLYCANS , *HEPARAN sulfate , *GENETICS - Abstract
The mucopolysaccharidoses (MPSs) are a group of rare lysosomal storage disorders caused by deficiency of enzymes catalyzing the stepwise degradation of glycosaminoglycans dermatan sulfate, heparan sulfate, keratan sulfate, chondroitin sulfate, and hyaluronic acid. There are seven groups of MPS, which are MPS-I (MPS-I-H or Hurler syndrome; MPS-I-S or Scheie syndrome; and MPS-I-HS or Hurler-Scheie syndrome), MPS- II (Hunter syndrome), MPS-III (Sanfilippo syndrome types A to D), MPS-IV (Morquio syndrome types A and B), MPS-VI (Maroteaux-Lamy syndrome), MPS-VII (Sly syndrome), and MPS-IX (Natowicz syndrome). All are inherited as autosomal recessive diseases, with the exception of Hunter syndrome, which follows an X-linked recessive inheritance pattern. The MPSs affect multiple organ systems (including bone, heart, and visceral organs), leading to organ failure. Involvement of central nervous system occurs only in the forms with heparan sulfate accumulation, that is, MPS-I, MPS-II, MPS-III, and MPS-VII. Therapy is available for MPS-I, MPS-II, MPS-IV, and MPS-VI. This review provides a case-based overview of the different forms of MPS with neurological involvement. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Neurological Involvement in Tetrahydrobiopterin Deficiency.
- Author
-
Mascaro, Italia, Ceravolo, Ferdinando, Ferraro, Stefania, Procopio, Daniela, Falvo, Francesca, Grisolia, Michele, Leone, Giuseppina, Salpietro, Vincenzo, Polizzi, Agata, Ruggieri, Martino, and Concolino, Daniela
- Subjects
TETRAHYDROBIOPTERIN ,COFACTORS (Biochemistry) ,HYDROXYLATION ,PHENYLALANINE ,TYROSINE ,HOMOVANILLIC acid ,PTERIDINES - Abstract
Tetrahydrobiopterin (BH4) is a natural and essential cofactor for the enzymatic hydroxylation of phenylalanine (Phe) and tyrosine (Tyr), and for two tryptophan hydroxylases, three nitric oxide synthases, and glyceryl-ether monooxygenase. Five separate genetic conditions affecting BH4 synthesis or recycling have been identified so far, including deficiency in (1) 6- pyruvoyltetrahydropterin synthase; (2) dihydropteridine reductase; (3) GTP cyclohydrolase I; (4) sepiapterin reductase; and (5) pterin-4α-carbinolamine dehydratase. These disorders cause hyperphenylalaninemia and impaired synthesis of serotonin and dopamine since tyrosine hydroxylase and neuronal tryptophan hydroxylase require BH4 and serotonin/dopamine products (5-hydroxytryptophan and L-dopa). All these five genetic conditions can be identified by newborn screening procedures due to elevated blood levels of Phe (with the sole exception of sepiapterin reductase deficiency). BH4 loading tests and measurement of neurotransmitter metabolites, pterins, and folates in cerebrospinal fluid can add further important information on disease severity. Untreated patients develop a complex neurological phenotype, which includes Parkinson-like features, brain degeneration, and early death. The gold standard treatment of severe disorders of BH4 metabolism is based on replacement therapy with BH4, 5-hydroxytryptophan, L-dopa, and carbidopa, with the addition, in certain cases, of folinic acid supplements and pramipexole. Dopamine agonists can improve L-dopa therapy, making treatment easier, relieving symptoms, stabilizing clinical course, and possibly ameliorating long-term outcomes. The outcome of patients with disorders of biopterin synthesis can be favorable, with either normal or near-normal cognition, and with some residual neurological symptoms usually manifesting diurnal variation, that is, worst when patients become tired or when the dosage or interval for medications is inadequate. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Pathobiological Insights into the Newly Targeted Therapies of Lysosomal Storage Disorders.
- Author
-
Sestito, Simona, Ceravolo, Ferdinando, Falvo, Francesca, Nicoletti, Angela, Stefanelli, Ettore, Apa, Rosalbina, Salpietro, Vincenzo, Polizzi, Agata, Ruggieri, Martino, and Concolino, Daniela
- Subjects
THERAPEUTICS ,LYSOSOMAL storage diseases ,METABOLIC disorders ,THERAPEUTIC use of enzymes ,MUCOPOLYSACCHARIDOSIS treatment ,BLOOD-brain barrier ,BLOOD-brain barrier disorders ,PATIENTS ,DISEASE risk factors - Abstract
Lysosomal storage disorders (LSDs) are a heterogeneous group of inborn errors of metabolism caused by inherited deficiencies of any of the lysosomal functions, leading to the accumulation of undegraded substrates in multiple tissues and organs. Two-third of LSDs involves the central nervous system, thus representing the most common cause of pediatric neurodegenerative diseases. Substantial progress has been made in our understanding of the pathophysiology of LSDs, leading to newly targeted therapeutic options. Enzyme replacement therapy (ERT) is currently available for seven LSDs including Gaucher disease, Fabry disease, Pompe disease, and mucopolysaccharidosis (MPS) I (Hurler disease), II (Hunter disease), IV A (Morquio A), and VI (Maroteaux-Lamy disease). ERT reduces lysosomal storage, thus slowing or sometimes avoiding progressive visceral damage altogether. However, ERT is unable to cross the blood-brain barrier (BBB), thus lacking efficacy on neurological manifestations. In patients with MPS I (Hurler disease) under 2 years of age and in selected patients with other LSD, hematopoietic stem cell transplantation is indicated. To bypass the BBB, other approaches, using small molecules are currently being tested and include substrate reduction therapy, which decreases the amount of substrate (currently available for type 1 Gaucher disease and for Niemann-Pick type C disease) and pharmacological chaperones, which enhance the residual activity of the mutant enzyme. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Neurological Involvement in Inherited Metabolic Diseases: An Overview.
- Author
-
Ceravolo, Ferdinando, Sestito, Simona, Falvo, Francesca, Salpietro, Vincenzo, Polizzi, Agata, Ruggieri, Martino, Bruno, Mercuri Francesco, and Concolino, Daniela
- Subjects
METABOLIC disorders ,METABOLIC disorder treatment ,PHENOTYPES ,INBORN errors of metabolism ,PERIPHERAL neuropathy ,GENETICS - Abstract
Neurological involvement is a typical feature of several inherited metabolic diseases. The onset of signs and/or symptoms may appear as early as the first days of life or after an interval of normal or near-normal growth and development. Metabolic decomposition usually presents with a severe clinical phenotype, which include poor feeding, vomiting, lethargy, seizures, and loss of consciousness. This spectrum of manifestations is often fatal; however, severe neurological sequelae and/or regression of neurodevelopmental milestones can be the prominent signs in those who survive. Overall, treatable inborn errors of metabolism can be divided in three groups, namely: (Group 1) inborn errors of intermediary metabolism giving rise to acute or chronic intoxication; (Group 2) inborn errors of intermediary metabolism affect in genergetic processes; and (Group 3) inborn errors involving cellular organelles, including lysosomal, peroxisomal, glycosylation, and cholesterol synthesis defects. The spectrum of neurological manifestations includes developmental delay, seizures and epilepsy, pyramidal and extrapyramidal signs, movement disorders, vision and hearing impairment, peripheral neuropathy, and psychiatric abnormalities. The main anatomical/imaging patterns reflects selective vulnerability of nervous system substance and include atrophy, (predominantly) symmetrical abnormalities, and dysmyelination, As several patients with neurometabolic diseases responds favorably to therapeutic trials, early detection and early intervention is of utmost importance to prevent catabolic-related damage and to revert to normal or near-normal parameters neurodevelopmental milestones. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Neurological Findings in Anderson-Fabry Disease.
- Author
-
Nicoletti, Angela, Sestito, Simona, Falvo, Francesca, Mascaro, Italia, Moricca, Maria Teresa, Salpietro, Vincenzo, Polizzi, Agata, Ruggieri, Martino, Bruno, Mercuri Francesco, and Concolino, Daniela
- Subjects
ANGIOKERATOMA corporis diffusum ,X-linked genetic disorders ,GALACTOSIDASES ,THERAPEUTIC use of enzymes ,PAIN management ,HEART failure risk factors ,GENETIC disorder treatment - Abstract
Anderson-Fabry disease (AFD) is an X-linked lysosomal storage disorder caused by mutations in the α-galactosidase A gene on chromosome Xq22, resulting in α-galactosidase A enzyme deficiency. It is characterized by progressive accumulation of lipids (e.g., globotriaosylceramide) in the lysosomes of a variety of cell types, including neural cells. Neurological manifestations, other than cerebrovascular accidents, include small fiber neuropathy and dysautonomic disorders. Small fiber peripheral neuropathy often is clinically manifested at young ages. Peripheral pain can be chronic and/or can occur as provoked attacks of excruciating pain. Manifestations of dysfunction of small autonomic fibers may include impaired sweating, gastrointestinal dysmotility, and abnormal pain perception. Patients with AFD often remain undiagnosed until the emergence of a more typical clinical manifestation, characterized by chronic renal and cardiac failure. Early clinical benefits of enzyme replacement therapy include reduction of neuropathic pain, and adequate management of residual pain to a tolerable and functional level, which can substantially improve the quality of these patients. Thus, it is important that physicians consider AFD in the differential diagnosis of neurological manifestations to provide an appropriate diagnostic and therapeutic workup. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.